EPS for Aurinia Pharmaceuticals (AUP) Expected At $-0.16; Rollins Has 1.67 Sentiment

October 12, 2017 - By Richard Conner

Analysts expect Aurinia Pharmaceuticals Inc (TSE:AUP) to report $-0.16 EPS on November, 3.They anticipate $0.09 EPS change or 36.00% from last quarter’s $-0.25 EPS. After having $-0.04 EPS previously, Aurinia Pharmaceuticals Inc’s analysts see 300.00% EPS growth. The stock increased 1.61% or $0.13 on October 12, reaching $8.21. About 24,932 shares traded. Aurinia Pharmaceuticals Inc (TSE:AUP) has 0.00% since October 12, 2016 and is . It has underperformed by 16.70% the S&P500.

Rollins, Inc. is a service company, which operates in pest and termite control business segment. The company has market cap of $10.38 billion. The Company, through its subsidiaries, provides its services to both residential and commercial clients in North America, Australia, and Europe with international franchises in Central America, the Caribbean, the Middle East, Asia, the Mediterranean, Europe, Africa, Canada, Australia, and Mexico. It has a 57.11 P/E ratio. The Company’s subsidiaries include Orkin LLC. , Western Pest Services (Western), The Industrial Fumigant Company, LLC (IFC), HomeTeam Pest Defense (HomeTeam), Rollins Australia and Rollins Wildlife Services.




Aurinia Pharmaceuticals Inc. is a Canada clinical-stage biopharmaceutical firm operating in the field of nephrology and autoimmunity. The company has market cap of $682.81 million. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis . It currently has negative earnings. It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Since January 1, 0001, it had 0 buys, and 1 insider sale for $239,280 activity.

Reilly Herbert Faulkner Iii holds 3.67% of its portfolio in Rollins, Inc. for 144,614 shares. Jlb & Associates Inc owns 275,029 shares or 2.84% of their US portfolio. Moreover, Conestoga Capital Advisors Llc has 2.08% invested in the company for 979,583 shares. The New York-based Sandhill Capital Partners Llc has invested 2.02% in the stock. Eulav Asset Management, a New York-based fund reported 725,500 shares.

The stock increased 0.23% or $0.11 during the last trading session, reaching $47.59. About 433,537 shares traded. Rollins, Inc. (ROL) has risen 51.75% since October 12, 2016 and is uptrending. It has outperformed by 35.05% the S&P500.

Analysts await Rollins, Inc. (NYSE:ROL) to report earnings on October, 25. They expect $0.25 EPS, up 8.70% or $0.02 from last year’s $0.23 per share. ROL’s profit will be $54.53M for 47.59 P/E if the $0.25 EPS becomes a reality. After $0.25 actual EPS reported by Rollins, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts